Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is an **experimental multi-component cancer immunotherapy** that combines three distinct technologies: - **Interleukin-2 (IL-2):** a cytokine that stimulates proliferation and activation of cytotoxic CD8+ T cells and natural killer (NK) cells, commonly used as an immunotherapy to enhance anti-tumor immune responses[1][5]. - **ZIF-8 (Zeolitic Imidazolate Framework-8):** a metal-organic framework (MOF) nanomaterial often used to encapsulate biomolecules or drugs, protecting them from degradation and enabling controlled release. ZIF-8 can facilitate delivery of biomacromolecules such as cytokines to the tumor microenvironment (TME). - **Salmonella (attenuated strain):** genetically engineered or otherwise attenuated Salmonella bacteria which preferentially colonize tumors and act as a delivery vehicle for biologic therapies. Salmonella can modulate the tumor microenvironment, recruit immune cells, and be engineered for payload delivery[3][4][5]. **Mechanism of action:** - The Salmonella vector selectively colonizes tumors, stimulating local immune responses. - ZIF-8 encapsulation prolongs the stability and bioavailability of IL-2 and/or aids its targeted release at the tumor. - Locally delivered IL-2 activates cytotoxic T cells and NK cells, enhancing anti-tumor immunity while minimizing systemic toxicity. - The combined approach aims to overcome the rapid clearance and toxicity of systemic IL-2, while leveraging the immunomodulatory properties of bacteria and nanocarrier. **Current status:** This specific triple-combination (interleukin-2 + ZIF-8 + Salmonella) is not a marketed pharmaceutical but represents a line of experimental cancer immunotherapy under preclinical or early translational evaluation. Attenuated Salmonella engineered to deliver IL-2 (with or without encapsulation technologies) is under clinical study for several cancers; the ZIF-8-IL-2-Salmonella platform is referenced in preclinical studies as a tumor-targeted immunostimulant[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-2 + ZIF-8 + Salmonella.